| Sr. no. | API | Structure | Ther. Category | Specification | Status |
|---|---|---|---|---|---|
| 1 | Rifampin |  |
Antibacterial Hepatoencephalopathy | EP | Commercial DMF Available |
| 2 | Pinaverium Bromide |  |
IBS Antispasmodic | In house (ICH) | Commercial DMF Available< |
| 3 | Imatinib Mesylate |  |
Anticancer | EP/BP | Commercial DMF Available |
| 4 | Erlotinib Hydrochloride |  |
Anticancer | In house (ICH) | Commercial DMF Available |
| 5 | Soratenib tosylate |  |
Anticancer | In house (ICH) | Commercial DMF Available |
| 6 | Lenalidomide |  |
Anticancer | In house (ICH) | Commercial DMF Available |
| 7 | Ticagrelor |  |
Antiplatelet | In house (ICH) | Commercial DMF Available |
| 8 | Dastinib |  |
Anticancer | In house (ICH) | Commercial DMF Available |
| 9 | Sunitinib Malate |  |
Anticancer | In house (ICH) | Commercial DMF Available |
-
Available API's
| API in R&D Pipeline | |||||
|---|---|---|---|---|---|
| 1 | Tofacitinib Citrate | Rheumatoid Arthritis | |||
| 2 | Gefitinib | Anti Cancer | |||
| 3 | Ibrutinib | Anti Cancer | |||
| 4 | Enzalutamide | Anti Cancer | |||
| 5 | Pazopanib | Anti Cancer | |||
| 6 | Afatinib | Anti Cancer | |||
| 7 | Axitinib | Anti Cancer | |||
| 8 | Bosutinib | Anti Cancer | |||
| 9 | Nintedanib | Anti Cancer | |||
| 10 | Nilotinib | Anti Cancer | |||
| 11 | Empagliflogin | Anti Diabetic | |||
| 12 | Canagliflogin | Anti Diabetic | |||
| 13 | Dapagliflogin | Anti Diabetic | |||